Clinical Research Directory

Inclusion Criteria: 1. Healthy male and female subjects aged from 18 to 45 years; 2. Subject has a Body Mass Index (BMI) between 18.5 and 28.0 kg/m2 at screening and the weight of male subjects is not less than 50 kg, and the weight of female subjects is not less than 45 kg;; 3. Subjects who voluntarily participate and sign informed consent form; 4. Subjects who can communicate well with investigator and comply with the lifestyle restrictions specified in the protocol, and cooperate to complete the trial procedure; 5. Subjects willing to use reliable contraceptive methods throughout the trial and for 6 months after trial completion. Exclusion Criteria: 1. Medical history (current or past) that in the investigator's judgment may interfere with trial participation; 2. Surgical/medical conditions that may significantly affect drug pharmacokinetics (absorption, distribution, metabolism, excretion) or pose safety risks; 3. Occurrence of protocol-defined exclusionary events within 3 months prior to investigational product administration; 4. Use of any prescription/non-prescription medications (including herbal products) within 2 weeks prior to dosing; 5. Known hypersensitivity to any component of the investigational product or history of severe allergic reactions; 6. Positive serology for hepatitis B surface antigen, hepatitis C antibody, HIV antibody, and syphilis serum reaction; 7. Substance abuse history within 1 year prior to screening or positive urine drug screen; 8. Alcohol abuse history within 1 year or positive alcohol breath test; 9. Smoking ≥5 cigarettes/day on average during 3 months prior to screening; 10. Pregnant or lactating women; 11. Positive pregnancy test before study drug administration, or male and female subjects who refuse to use effective contraceptive methods during and for 6 months post-trial, or who have plans to donate sperm or eggs; 12. Poor compliance or any other condition that in the investigator's opinion renders the subject unsuitable for trial participation.